key: cord-0330742-kuziorl9 authors: Wali, Laxmikant; Karbiener, Michael; Chou, Scharon; Kovtunyk, Vitalii; Adonyi, Adam; Gösler, Irene; Contreras, Ximena; Stoeva, Delyana; Blaas, Dieter; Stöckl, Johannes; Kreil, Thomas R.; Gualdoni, Guido A.; Gorki, Anna-Dorothea title: Host-directed therapy with 2-Deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2 date: 2022-05-24 journal: bioRxiv DOI: 10.1101/2022.05.24.493068 sha: 968aa478c2889cddb964a6166362aedad499de14 doc_id: 330742 cord_uid: kuziorl9 Rhinoviruses (RVs) and coronaviruses (CoVs) upregulate host cell metabolic pathways including glycolysis to meet their bioenergetic demands for rapid multiplication. Using the glycolysis inhibitor 2-deoxy-D-glucose (2-DG), we confirm the dose-dependent inhibition of minor- and major-receptor group RV replication. We demonstrate that 2-DG suppresses viral positive-as well as negative-strand RNA synthesis, resulting in lower amounts of progeny virus and RV-mediated cell death. In tissue culture with physiologic glucose levels, 2-DG has a pronounced antiviral effect. Further, assessment of 2-DG’s intracellular kinetics revealed that the active intermediate, 2-DG6P, is stored intracellularly for several hours. Our concurrent study of 2-DG’s impact on pandemic SARS-CoV-2 and endemic HCoVs demonstrated a significant reduction in viral load. Collectively, these results suggest 2-DG to be a broad-spectrum antiviral. HIGHLIGHTS 2-DG, a glucose analogue, inhibits RV RNA replication and reduces RV-mediated cell death in vitro. 2-DG exhibits increased inhibitory activity against RV in physiological glucose concentrations in vitro. 2-DG attenuates viral load of pandemic and endemic CoVs in vitro. cannot be further metabolized by phosphoglucose isomerase [28] . This leads to 94 intracellular accumulation of 2-DG6P and arrest of glycolysis at the initial stage, 95 causing depletion of glucose derivatives and substrates crucial for viral replication 96 [29]. Previously, it has been demonstrated that 2-DG affects viral replication by 97 reverting virus-induced metabolic reprogramming of host cells [24] , [25] , [30] , [31] . 98 In the present study, we investigated the antiviral activity of 2-DG against minor-and 100 major-group RVs in epithelial cells including primary human nasal epithelial cells, the 101 main site of RV replication. Concomitantly, we explored the effect of glucose on the 102 antiviral activity of 2-DG and characterized 2-DG´s intracellular kinetics. To better 103 qPCR. qPCR was performed using SYBR green mix and primers as described in 146 Supplement Table 1 . For measuring intracellular viral RNA, gene expression was 147 normalized to HPRT using the Livak method [33] and expressed as fold change to 148 control (infected, but untreated). Primers HRV-B14_R and chimHRV-b14_R1 were 149 used for measurement of viral (-)RNA. For extracellular viral RNA, synthetic oligo 150 standard (HRV-B14_F, HRV-B14_R and HRV-B14 primer amplicon, Supplement 151 Table 1 ) were used to generate a standard curve for the calculation of viral copy 152 number by interpolation. Based on the qPCR data, the IC 50 was calculated using 153 least square regression on Prism 9.0.2. used in the above-mentioned study, but also for additional RV stains from the minor-199 group (RV-A1B, RV-A2) and the major-group (RV-A89, RV-A16, RV-A54). HeLa Ohio 200 cells were infected under conventional culture conditions using a medium containing 201 2 g/L glucose. We found that 2-DG treatment led to a dose-dependent reduction in 202 intracellular viral RNA levels of all major-and minor-group RVs tested ( Figure 1A ). concentration in conventional cell culture media ranges from 2 g/L to 4.5 g/L. This is 220 much higher than in vivo glucose levels (e.g., in the blood, which is in the range of 221 3.9 to 5.6 mmol/L i.e., 0.7 to 1 g/L). To understand the uptake and activity of 2-DG at 222 physiological glucose levels, we reduced the glucose concentration in the cell culture 223 medium to 1 g/L to mimic a setting corresponding to human plasma. As in the 224 conventional cell culture setup above (Figure 1 ), HeLa Ohio cells were separately infected with six different RV strains. Again, we observed that 2-DG suppressed RV 226 replication in a dose-dependent manner, with 30 mM 2-DG leading to complete 227 abolishment of RV replication (Figure 2A ). In addition, 3 mM and 10 mM 2-DG 228 caused a pronounced reduction in intracellular viral RNA for all tested RV strains 229 ( Figure 2A ). In line with these results, the absolute half-maximal inhibitory Table 2 ). It should be noted that the glucose concentration in fluid lining the nose and 335 lung epithelium in humans is around 12.5 times lower than in plasma [36] . Therefore, 336 it can be anticipated that 2-DG exhibits even higher antiviral efficacy in therapeutic 337 target tissues. However, additional studies in models closer to the physiologic 338 conditions are warranted to test this hypothesis. 339 In the next step, we characterized the intracellular kinetics of 2-DG. In the cell, 2-DG 341 is phosphorylated to 2-DG6P, leading to its intracellular accumulation. Cytochalasin 342 B, an inhibitor of the glucose transporter, was used as a control to ensure 2-DG6P 343 specificity in our set-up (data not shown). Overall, we found that 2-DG6P was 344 detectable up to several hours in HeLa Ohio cells and HNEC after a short incubation Picornavirus infections: a primer for the 485 practitioner Epidemiological and clinical features 488 of human coronavirus infections among different subsets of patients Pulmonary and extrapulmonary complications of human 492 rhinovirus infection in critically ill patients Is 496 respiratory viral infection really an important trigger of asthma exacerbations in 497 children? Unexpectedly Higher Morbidity and Mortality of Hospitalized 500 Elderly Patients Associated with Rhinovirus Compared with Influenza Virus 501 Respiratory Tract Infection COVID-19 is an emergent disease of aging The COVID-19 Pandemic and the 16 Trillion 506 Virus The Economic 508 Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United 509 States Sequencing and Analyses of All Known Human 512 Members of the low density lipoprotein receptor family mediate 515 cell entry of a minor-group common cold virus Major and minor group rhinoviruses elicit differential 519 signaling and cytokine responses as a function of receptor-mediated signal 520 transduction Mechanism of human rhinovirus infections Coronavirus Genomics 525 and Bioinformatics Analysis Identification of a new human coronavirus Recovery in tracheal organ cultures of novel viruses from patients with 531 respiratory disease A New Virus Isolated from the Human 535 Respiratory Tract Circulation of genetically distinct contemporary human 538 coronavirus OC43 strains Coronavirus infections in 541 working adults. Eight-year study with 229 E and OC 43 Effects of a 'new' human 545 respiratory virus in volunteers Genetic 549 comparison among various coronavirus strains for the identification of potential 550 vaccine targets of SARS-CoV2 Viral activation of cellular metabolism Hijacking the 556 Supplies: Metabolism as a Novel Facet of Virus-Host Interaction Viral hijacking of cellular 559 metabolism Elevated Glucose Levels Favor SARS-CoV-2 Infection Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis Rhinovirus induces an anabolic reprogramming in host 566 cell metabolism essential for viral replication 2-Deoxyglucose 570 transport and metabolism in Caco-2 cells The importance of glucose transport activity as the rate-limiting 574 step of 2-deoxyglucose uptake in tumor cells in vitro Energy disruptors: 578 rising stars in anticancer therapy? 2-Deoxyglucose: An anticancer and antiviral 581 therapeutic, but not any more a low glucose mimetic Glycolysis Is an Intrinsic Factor for Optimal 584 Replication of a Norovirus Dengue Virus 587 Induces and Requires Glycolysis for Optimal Replication Specific Assay of Negative Strand Template to 590 Quantify Intracellular Levels of Rhinovirus Double-Stranded RNA Analysis of Relative Gene Expression Data 593 Using Real-Time Quantitative PCR and the 2−ΔΔCT Method Apoptotic events 599 induced by human rhinovirus infection Sweet talk: insights into the 602 nature and importance of glucose transport in lung epithelium Rhinovirus RNA Polymerase Replication 608 and Inhibitors of Enteroviruses and Parechoviruses Asthmatic bronchial epithelial cells have a deficient innate 611 immune response to infection with rhinovirus Proteomics of SARS-CoV-2-infected host cells reveals 614 therapy targets Exploitation of 616 glycosylation in enveloped virus pathobiology Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-620 CoV-2 multiplication in host cells and weakens the infective potential of 621 progeny virions